We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
FDA Commissioner Scott Gottlieb and CBER director Peter Marks on Wednesday announced enforcement efforts the agency is taking against stem cell clinics and manufacturers that put patients at risk by marketing unapproved products.